Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 2.3K citations

Medicine, Oncology, Pharmacotherapy +15

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making

Hans‐Joachim Schmoll, Eric Van Cutsem, Alexander Stein et al. · Annals of Oncology · 2012 · 1.5K citations · Full text

Medicine, Oncology, Surgery +17

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

Jaafar Bennouna, Javier Sastre, Dirk Arnold et al. · The Lancet Oncology · 2012 · 1.2K citations · Full text

Medicine, Oncology, Pharmacology +10

Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial

Fairooz F. Kabbinavar, Joseph J. Schulz, Michael McCleod et al. · Journal of Clinical Oncology · 2005 · 933 citations · Full text

Medicine, Oncology, Pharmacotherapy +16